Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ONCY 
Oncolytics Biotech Inc (ONCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ONCY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -17.31% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.34M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 243813 | Beta 1.49 | 52 Weeks Range 0.53 - 1.53 | Updated Date 03/31/2025 |
52 Weeks Range 0.53 - 1.53 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.1345 | Actual -0.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -74.11% | Return on Equity (TTM) -189.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37310318 | Price to Sales(TTM) - |
Enterprise Value 37310318 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.79 | Shares Outstanding 86421600 | Shares Floating 82982877 |
Shares Outstanding 86421600 | Shares Floating 82982877 | ||
Percent Insiders 4.35 | Percent Institutions 1.62 |
Analyst Ratings
Rating 4.29 | Target Price 4.83 | Buy 5 | Strong Buy 2 |
Buy 5 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Oncolytics Biotech Inc
Company Overview
History and Background
Oncolytics Biotech Inc. is a late-stage clinical development company focused on developing oncolytic viruses as potential cancer therapeutics. Founded in 1998, Oncolytics has focused on its lead product, pelareorep, a non-pathogenic, proprietary isolate of the reovirus, for the treatment of various cancers.
Core Business Areas
- Oncolytic Virus Development: Focuses on the development and commercialization of oncolytic viruses for cancer treatment, with pelareorep as the lead product.
Leadership and Structure
The leadership team consists of individuals with experience in oncology drug development and commercialization. The company is structured around research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- Pelareorep: Pelareorep is Oncolytics' lead product, an intravenously delivered immuno-oncolytic virus. It is currently in various clinical trials for multiple cancer types. Market share data is not readily available due to the product being in clinical trials, but potential competitors include companies developing other oncolytic viruses or immuno-oncology therapies, such as Amgen (T-VEC), Merck (Keytruda), and Bristol-Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The oncology therapeutics market is large and rapidly growing, driven by an aging population and advancements in cancer research. Immuno-oncology and oncolytic viruses are emerging areas with significant potential.
Positioning
Oncolytics is positioned as a company focused on developing oncolytic viruses for cancer treatment, with pelareorep being its lead product. Competitive advantages potentially include the virus's ability to selectively infect and lyse cancer cells while stimulating an immune response.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Oncolytics is positioned to capture a portion of this market with successful development and commercialization of pelareorep, particularly within specific cancer indications.
Upturn SWOT Analysis
Strengths
- Novel oncolytic virus technology
- Potential for combination therapies
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a single lead product
- High development costs and regulatory hurdles
- Limited commercialization experience
- Need for substantial additional funding
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results
- Growing interest in immuno-oncology
Threats
- Competition from other cancer therapies
- Clinical trial failures
- Regulatory setbacks
- Funding constraints
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- BMY
Competitive Landscape
Oncolytics faces competition from established pharmaceutical companies with broader pipelines and greater resources. Its competitive advantage lies in its novel oncolytic virus technology and potential for combination therapies. Given it is in clinical trials, market share is not accurate, so the above values are placeholders.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Oncolytics' historical growth has been driven by clinical trial progress and partnerships.
Future Projections: Future growth depends on the successful development and commercialization of pelareorep. Analyst projections vary based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include progressing clinical trials of pelareorep in various cancer types and seeking partnerships for development and commercialization.
Summary
Oncolytics Biotech is a clinical-stage company with a focus on oncolytic virus technology. The company's lead product, pelareorep, shows promise but faces challenges with clinical trials and regulatory hurdles. Securing partnerships and demonstrating clinical efficacy are crucial for future success. It needs to overcome funding constraints and successfully navigate regulatory landscapes.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (if available)
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investments in biotechnology companies are highly speculative and involve significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oncolytics Biotech Inc
Exchange NASDAQ | Headquaters Calgary, AB, Canada | ||
IPO Launch date 1999-11-08 | Interim CEO & Chairman of the Board Mr. Wayne F. Pisano M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | |
Full time employees 28 | |||
Oncolytics Biotech Inc. operates as a clinical-stage biopharmaceutical company. The company develops pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms to improve the ability of the immune system to fight cancer, making tumors more susceptible to a range of oncology treatments. It entered an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.